Felhasznált irodalom
*fontos közlemény
1. Karagiannis TC, El-Osta A. RNA interference and potential therapeutic applications of short
interfering RNAs. Cancer Gene Therapy 2005;12: 787-795.
2. Izquierdo M. Short interfering RNAs as a tool for cancer gene therapy. Cancer Gene Therapy
2005;12:217-227.
3. * Kimchi ET, Posner MC, Park JO és mtsai Progression of Barrett’s Metaplasia to Adenocarcinoma
Is Associated with the Suppression of the transcriptional Programs of Epidermal Differentiation.
Cancer Res 2005; 65: 3146-54.
4. * Gomes LI, Esteves GH, Carvalho AF és mtsai Expression Profi le of Malignant and Nonmalignant
Lesions of Esophagus and Stomach: Differential Activity of Functional Modules Related to
Infl ammation and Lipid Metabolism. Cancer Res 2005; 65: 7127-36.
5. Cheng P, Gong J, Wang T, és mtsai Gene expression in Barrett’s esophagus and refl ux
esophagitis induced by gastroduodenoesophageal refl ux in rats. World J Gastroenterol 2005;
11: 3277-3280.
6. Souza RF, Shewmake KL, Shen Y és mtsai Differences in ERK activation in squamous mucosa
in patients who have gastroesophageal refl ux disease with and without Barrett’s esophagus.
Am J Gastroenterol 2005;100:551-9.
7. Zou H, Molina JR, Harrington JJ és mtsai Aberrant methylation of secreted frizzled-related
protein genes in esophageal adenocarcinoma and Barrett’s esophagus. Int J Cancer 2005;116:
584-91.
8. Casson AG, Zheng Z, Evans SC és mtsai Cyclin D1 Polymorphism (G870A) and Risk for
Esophageal Adenocarcinoma. Cancer 2005;104:730–9.
9. Lewis SJ, Simth GD. Alcohol, ALDH2, and Esophageal Cancer: A Meta-analysis Which Illustrates
the Potentials and Limitations of a Mendelian Randomization Approach. Cancer Epidemiol
Biomarkers Prev 2005;14:1967–71.
10. * Hu N, Wang C, Hu Y és mtsai Genome-Wide Association Study in Esophageal Cancer Using
GeneChip Mapping 10K Array. Cancer Res 2005; 65: 2542-6.
11. ZHANG X, MIAO X, TAN W és mtsai Identifi cation of Functional Genetic Variants in
Cyclooxygenase-2 and Their Association With Risk of Esophageal Cancer. Gastroenterology
2005;129:565-76.
12. Marsman WA, Buskens CJ, Wesseling JG és mtsai Gene therapy for barrett’s esophagus: adenoviral
gene transfer in different intestinal models. Cancer Gene Therapy 2005;12: 778–786.
Genetika, pathológia | 373
374 | Gastro Update 2006
13. * Cui DX, Zhang L, Yan XJ, és mtsai A microarray-based gastric carcinoma prewarning system.
World J Gastroenterol 2005; 11: 1273-1282.
14. Terashima M, Maesawa C, Oyama K és mtsai Gene expression profi les in human gastric cancer:
expression of maspin correlates with lymph node metastasis. Br J Cancer 2005;92:1130-6.
15. * Yu CD, Xu SH, Mou HZ, és mtsai Gene expression profi le differences in gastric cancer,
pericancerous epithelium and normal gastric mucosa by gene chip. World J Gastroenterol
2005; 11: 2390-2397.
16. Galamb O, Sipos F, Fischer K és mtsai The Results of the Expression Array Studies Correlate
and Enhance the Known Genetic Basis of Gastric and Colorectal Cancer. Cytometry Part B
(Clinical Cytometry) 2005;68B: 1-17.
17. Palli D, Saieva C, Luzzi I és mtsai Interleukin-1 gene polymorphisms and gastric cancer risk in
a high-risk Italian population. Am J Gastroenterol 2005;100:1941-8.
18. Rocha GA, Guerra JB, Rocha AMC és mtsai IL1RN polymorphic gene and cagA-positive status
independently increase the risk of noncardia gastric carcinoma. Int J Cancer 2005;115:678-
83.
19. Taguchi A, Ohmiya N, Shirai K és mtsai Interleukin-8 Promoter Polymorphism Increases the
Risk of Atrophic Gastritis and Gastric Cancer in Japan. Cancer Epidemiol Biomarkers Prev
2005;14:2487–93.
20. Ohyauchi M, Imatani A, Yonechi M és mtsai The polymorphism interleukin 8 2251 A/T infl uences
the susceptibility of Helicobacter pylori related gastric diseases in the Japanese population.
Gut 2005;54:330–335.
21. Chang YW, Jang JY, Kim NH és mtsai Interleukin-1B (IL-1B) polymorphisms and gastric mucosal
levels of IL-1b cytokine in Korean patients with gastric cancer. Int J Cancer 2005;114:465-71.
22. Li Z, Chen D, Zhang C és mtsai HLA polymorphisms are associated with Helicobacter pylori
infected gastric cancer in a high risk population, China. Immunogenetics 2005;56:781-787.
23. Hellmig S, Fischbach W, Goebeler-Kolve ME és mtsai Association study of a functional Toll-like
receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue
lymphoma. Leuk Lymphoma 2005;46:869-72.
24. Hellmig S, Fischbach W, Goebeler-Kolve ME és mtsai A Functional Promoter Polymorphism
of TNF-α Is Associated with Primary Gastric B-Cell Lymphoma. Am J Gastroenterol
2005;100:2644–2649
25. Kidd M, Eivk G, Shapiro MD és mtsai Microsatellite Instability and Gene Mutations in Transforming
Growth Factor-Beta Type II receptor Are Absent in Small Bowel Carcinoid Tumors. Cancer
2005;103:229-36.
26. Min Y, Adachi Y, Yamamoto H és mtsai Insulin-like growth factor I receptor blockade enhances
chemotherapy and radiation responses and inhibits tumour growth in human gastric cancer
xenografts. Gut 2005;54:591–600.
27. Zhao ZG, Shen WL. Heat shock protein 70 antisense oligonucleotide inhibits cell growth and
induces apoptosis in human gastric cancer cell line SGC-7901. World J Gastroenterol 2005;
11: 73-78.
28. Hunt KA, McGovern DPB, Kumar PJ és mtsai A common CTLA4 haplotype associated with
coeliac disease. Eur J Hum Genet 2005;13:440-4.
29. Lio D, Scola L, Forte GI és mtsai TNFa, IFNg and IL-10 gene polymorphisms in a sample of
Sicilian patients with coeliac disease. Dig Liv Dis 2005;37:756–760.
30. FURUTA T, SAGEHASHI Y, SHIRAI N és mtsai Infl uence of CYP2C19 Polymorphism and
Helicobacter pylori Genotype Determined From Gastric Tissue Samples on Response to Triple
Therapy for H pylori Infection. Clin gastroenterol Hepatol 2005;3:564-73.
31. Muramatsu A, Azuma T, Okuda T és mtsai Association between interleukin-1b-511C/T
polymorphism and refl ux esophagitis in Japan. J Gastroenterol 2005; 40:873–877.
32. Burt R, Neklason DW. Genetic testing for inherited colon cancer. Gastroenterology
2005;128:1696-1716.
33. * Kairupan CF, Meldrum CJ, Crooks R és mtsai Mutation analysis of the MYH gene in an
Australian series of colorectal polyposis patients with or without germline APC mutations.Int J
Cancer 2005;116:73-7.
34. * Hampel H, Frankel WL, Martin E és mtsai Screening for the Lynch Syndrome (Hereditary
Nonpolyposis Colorectal Cancer). NEJM 2005;352:1851-60.
35. * Velayos FS, Allen BA, Conrad PG és mtsai Low rate of microsatellite instability in young patients
with adenomas: reassessing the Bethesda guidelines. Am J Gastroenterol 2005;100:1143-9.
36. * Mangold E, Pagenstecher C, Friedl W és mtsai Spectrum and frequencies of mutations in
MSH2 and MLH1 identifi ed in 1,721 german families suspected of hereditary nonpolyposis
colorectal cancer. Int J Cancer 2005;116:692-702.
37. BAUDHUIN LM, FERBER MJ, WINTERS JL és mtsai Characterization of hMLH1 and hMSH2
Gene Dosage Alterations in Lynch Syndrome Patients. Gastroenterology 2005;129:846-54.
38. HITCHINS M, WILLIAMS R, CHEONG K és mtsai MLH1 Germline Epimutations as a Factor in
Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 2005;129:1392-99.
39. Czako L, Tiszlavicz L, Takacs R és mtsai Az első magyar hereditaer nem polypoticus colorectalis
carcinoma család molekuláris vizsgálata: az MSH2 gén új mutációja. Orv Hetil 2005;146:1009-
16.
40. Losi L, Di Gregorio C, Pedroni M és mtsai Molecular genetic alterations and clinical features
in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer
syndromes. Am J Gastroenterol. 2005;100:2280-7.
41. * Mueller-Koch Y, Vogelsang H, Kopp R, és mtsai HNPCC – clinical and molecular evidence for
a new entity of hereditary colorectal cancer. Gut;54:1733-40.
42. Westphalen AA, Russell AM, Buser M és mtsai Evidence for genetic anticipation in hereditary
non-polyposis colorectal cancer. Hum Genet 2005;116:461-465.
43. Alhopuro P, Katajisto P, Lehtonen R és mtsai Mutation analysis of three genes encoding novel
LKB1-interacting proteins, BRG1, STRADa, and MO25a, in Peutz–Jeghers syndrome.Br J
Cancer 2005;92:1126-9.
44. Luo L, Chen WD, Pretlow TP. CpG island methylation in aberrant crypt foci and cancers from
the same patients. Int J Cancer 2005;115: 747-51.
45. Wang H, MacNaughton WK. Overexpressed B-Catenin Blocks Nitric Oxide–Induced Apoptosis
in Colonic Cancer Cells. Cancer Res 2005;65:8604-7.
46. Fidder HH, Figer A, Geva R és mtsai Genetic analyses in consecutive israeli jewish colorectal
cancer patients. Am J Gastroenterol 2005;100:1376-80.
47. Zauber NP, Sabbath-Solitare M, Marotta S és mtsai Clinical and Genetic Findings in an
Ashkenazi Jewish Population with Colorectal Neoplasms. Cancer 2005;104:719-29.
48. Tranah GJ, Giovannucci E, Ma J és mtsai APC Asp1822Val and Gly2502Ser Polymorphisms and
Risk of Colorectal Cancer and Adenoma. Cancer Epidemiol Biomarkers Prev 2005;14:863–70.
49. * Oda S, Maehara Y, Ykeda Y, és mtsai Two modes of microsatellite instability in human cancer:
differential connection of defective DNA mismatch repair to dinucleotide repeat instability.
Nucleic Acid Res 2005;33:1628-36.
50. Kono S, Chen K. Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal
cancer and adenoma. Cancer Sci 2005;96:535-42.
51. Marchand LL, Wilkens LR, Kolonel LN és mtsai The MTHFR C677T Polymorphism and Colorectal
Cancer: The Multiethnic Cohort Study. Cancer Epidemiol Biomarkers Prev 2005;14:1198–
203.
52. Broll R, Busch P, Duchrow M és mtsai Infl uence of thymidylate synthase and p53 protein
expression on clinical outcome in patients with colorectal cancer. Int J Colorectal Dis
2005;20:94-102.
53. Tang KS, Chiu HF, Chen HH, és mtsai Link between colorectal cancer and polymorphisms
in the uridine-diphosphoglucuronosyltransferase 1A7 and 1A1 genes. World J Gastroenterol
2005; 11: 3250-3254.
Genetika, pathológia | 375
376 | Gastro Update 2006
54. Komuro K, Tada M, Tamoto E és mtsai Right- and left-sided colorectal cancers display distinct
expression profi les and the anatomical stratifi cation allows a high accuracy prediction of lymph
node metastasis. J Surg Res 2005;124:216-24.
55. * Birkenkamp-Demtroder K, Olesen SH, Sorensen FB, és mtsai Differential gene expression in
colon cancer of the caecum versus the sigmoid and rectosigmoid. Gut 2005;54:374-84.
56. Chiu ST, Hsieh FJ, Chen SW és mtsai Clinicopathologic Correlation of Up-regulated Genes
Identifi ed Using cDNA Microarray and Real-time Reverse Transcription-PCR in Human
Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2005;14:437–43.
57. Friederichs J, Rosenberg R, Mages J és mtsai Gene expression profi les of different clinical stages
of colorectal carcinoma: toward a molecular genetic understanding of tumor progression. Int J
Colorectal Dis 2005;20: 391-402.
58. D’Arrigo A, Belluco C, Ambrosi A és mtsai Metastatic transcriptional pattern revealed by gene
expression profi ling in primary colorectal carcinoma. Int J Cancer 2005;115:256-62.
59. * Giacomini CP, Leung SY, Chen X és mtsai A Gene Expression Signature of Genetic Instability
in Colon Cancer. Cancer Res 2005;65:9200-5.
60. Lawes DA, Pearson T, SenGupta S és mtsai The role of MLH1, MSH2 and MSH6 in the
development of multiple colorectal cancers. Br J Cancer 2005;93: 472-7.
61. Zhu M, Li J, Zhang X és mtsai Large genomic aberrations in MSH2 and MLH1 genes are
frequent in Chinese colorectal cancer. Cancer Genet Cytogenet 2005;160:61–67.
62. Hsieh JS, Lin SR, Chang MY és mtsai APC, K-ras and p53 gene mutations in colorectal cancer
patients: correlation to clinicopathologic features and postoperative surveillance. Am Surg
2005;71:336-43.
63. AKINO K, TOYOTA M, SUZUKI H és mtsai The Ras Effector RASSF2 Is a Novel Tumor-Suppressor
Gene in Human Colorectal Cancer. Gastroenterology 2005;129:156-69.
64. Samowitz WS, Sweeney C, Herrick J és mtsai Poor Survival Associated with the BRAF V600E
Mutation in Microsatellite-Stable Colon Cancers. Cancer Res 2005;65:6063-9.
65. Dejmek J, Dejmek A, Safholm A és mtsai Wnt-5a Protein Expression in Primary Dukes B Colon
Cancers Identifi es a Subgroup of Patients with Good Prognosis. Cancer Res 2005;65:9142-6.
66. Alhopuro P, Alazzouzi H, Sammalkorpi H és mtsai SMAD4 Levels and Response to 5-Fluorouracil
in Colorectal Cancer. Clin Cancer Res 2005;11:6311-16.
67. Inoue T, Hibi K, Nakayama G és mtsai Expression level of thymidylate synthase is a good
predictor of chemosensitivity to 5-fl uorouracil in colorectal cancer. J Gastroenterol 2005;
40:143–147.
68. Hong Y, Eu KW, Seow-Choen F és mtsai GG genotype of cyclin D1 G870A polymorphism is
associated with increased risk and advanced colorectal cancer in patients in Singapore. Eur
J Cancer 2005;41:1037-44.
69. Robinson JP, Johnson VL, Rogers PA és mtsai Evidence for an Association between Compound
Heterozygosity for Germ Line Mutations in the Hemochromatosis (HFE) Gene and Increased
Risk of Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1460–3.
70. Rasinpera H, Forsblom C, Enattah NS és mtsai The C/C-13910 genotype of adult-type
hypolactasia is associated with an increased risk of colorectal cancer in the Finnish population.
Gut 2005;54:643–647.
71. Ali IU, Luke BT, Dean M és mtsai Allellic variants in regulatory regions of cyclooxygenase-2:
association with advanced colorectal adenoma. Br J Cancer 2005;93:953-9.
72. Papaconstantinou I, Theodoropoulos G, Gazouli M és mtsai Association between mutations
in the CARD15/NOD2 gene and colorectal cancer in a Greek population. Int J Cancer
2005;114:433-35.
73. Slattery ML, Sweeney C, Murtaugh M és mtsai Associations between ERa, ERb, and AR Genotypes
and Colon and Rectal Cancer. Cancer Epidemiol Biomarkers Prev 2005;14(12):2936–42.
74. Wada-Hiraike O, Yano T, Nei T és mtsai The DNA mismatch repair gene hMSH2 is a potent
coactivator of oestrogen receptora.Br J Cancer 2005;92:2286-91.
75. Barrier A, Boelle PY, Lemoine A és mtsai Gene Expression Profi ling of Nonneoplastic Mucosa
May Predict Clinical Outcome of Colon Cancer Patients. Dis Colon Rectum 2005. published
online 3. October 2005.
76. * Lentz F, Tran A, Rey E és mtsai Pharmacogenomics of fl uorouracil, irinotecan and oxaliplatin
in hepatic metastases of colorectal cancer: clinical implications. Am J Pharmacogenomics
2005;5:21-33.
77. Kweekel DM, Gelderblom H, Guchelaar HJ. Pharmacology of oxaliplatin and the use of
pharmacogenomics to individualize therapy. Cancer Treat Rev 2005;31:90-105.
78. Yu J, Shannon WD, Watso MA és mtsai Gene Expression Profi ling of the Irinotecan Pathway in
Colorectal Cancer. Clin Cancer Res 2005;11: 2063-62.
79. Vallbohmer D, Zhang W, Gordon M és mtsai Molecular determinants of cetuximab effi cacy. J
Clin Oncol 2005;23:3536-44.
80. Zhu H, Guo W, Zhang L és mtsai Bcl-XL small interfering RNA suppresses the proliferation of
5-fl uorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005;4:451–6.
81. Ting AH, Schubel KE, Herman JG és mtsai Short double-stranded RNA induces transcriptional
gene silencing in human cancer cells in absence of DNA methylation. Nat Genet 2005;37:906-
10.
82. Nesterova MV, Johnson NR, Stewart T és mtsai CpGImmunomer DNAEnhances Antisense
Protein KinaseARIA Inhibition ofMultidrug-Resistant Colon Carcinoma Growth in NudeMice:M
olecular Basis for Combinatorial Therapy. Clin Cancer Res 2005;11: 5950-55.
83. TU SP, CUI JT, LISTON P és mtsai Gene Therapy for Colon Cancer by Adeno-Associated Viral
Vector-Mediated Transfer of Survivin Cys84Ala Mutant. Gastroenterology 2005;128:361-75.
84. Newman B, Siminovitch KA. Recent advances in the Genetics of infl ammatory bowel disease.
Current Opin Gastroenterology 2005;21:401-7.
85. Gasche C, Grundtner P. Genotypes and phenotypes in Crohn’s disease: do they help in clinical
management? Gut 2005;54:162-7.
86. Hagymasi K, Tulassay Z. Genotype-phenotype associations in infl ammatory bowel disease.
Orv Hetil 2005;146:1767-73.
87. Hagymasi K, Tulassay Z. Pharmacogenetics of infl ammatory bowel disease. Orv Hetil
2005;146:1143-50.
88. * Silverberg MS, Satsangi J, Ahmad T és mtsai Toward an integrated clinical, molecular and
serological classifi cation of infl ammatory bowel disease: Report of a Working Party of the 2005
Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19, Suppl A:5-36.
89. Maeda S, Hsu LC, Liu H és mtsai NOD2 mutation in Crohn’s disease potentiates NF-kB activity
and IL-1b processing. Science 2005;307:734-8.
90. Kobayashi KS, Chamaillard M, Ogura Y és mtsai NOD2 dependent regulation of innate and
adaptive immunity in the intestinal tract. Science 2005;307:731-4.
91. Pierik M, De Hertogh G, Vermeire S és mtsai Epithelioid granulomas, pattern recognition
receptors, and phenotypes of Crohn’s disease. Gut 2005;54:223–227.
92. Büning C, Molnar T, Nagy F,és mtsai NOD2/CARD15 gene polymorphism in patients with
infl ammatory bowel disease: Is Hungary different? World J Gastroenterol 2005; 11: 407-411.
93. Nagy Z, Karadi O, Rumi G és mtsai Crohn’s Disease Is Associated with Polymorphism of
CARD15/NOD2 Gene in a Hungarian Population. Ann N Y Acad Sci. 2005;1051:45-51.
94. Pierik M, Yang H, Barmada MM és mtsai The IBD international genetics consortium provides
further evidence for linkage to IBD4 and shows gene-environment interaction. Infl amm Bowel
Dis 2005;11:1-7.
95. McGovern DP, Hysi P, Ahmad T és mtsai Association between a complex insertion/deletion
polymorphism in NOD1 (CARD4) and susceptibility to infl ammatory bowel disease. Hum Mol
Genet 2005;14:1245-50.
96. Ferreira AC, Almeida S, Tavares M és mtsai NOD2/CARD15 and TNFA, but not IL1B and IL1RN,
are associated with Crohn’s disease. Infl amm Bowel Dis 2005;11:331-9.
Genetika, pathológia | 377
378 | Gastro Update 2006
97. Kugathasan S, Loizides A, Babusukumar U és mtsai Comparative phenotypic and CARD15
mutational analysis among African American, Hispanic, and White children with Crohn’s
disease. Infl amm Bowel Dis 2005;11:631-8.
98. Jess T, Riis L, Jespersgaard C és mtsai Disease concordance, zygosity, and NOD2/CARD15
status: follow-up of a population-based cohort of Danish twins with infl ammatory bowel disease.
Am J Gastroenterol 2005;100:2486-92.
99. Annese V, Lombardi G, Perri F és mtsai Variants of CARD15 are associated with an aggressive
clinical course of Crohn’s disease–an IG-IBD study. Am J Gastroenterol 2005;100:84-92.
100. Gazouli M, Mantzaris G, Kotsinas A és mtsai Association between polymorphisms int he toll-like
receptor !, CD14 and CARD15/NOD2 and infl ammatory bowel disease in Greek population.
World J Gastroenterol 2005;11:681-5.
101 * Brand S, Staudinger T, Schnitzler F és mtsai The role of Toll-like receptor 4 Asp299Gly and
Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype
of Crohn’s disease. Infl amm Bowel Dis 2005;11:645-52.
102 Braat H, Stokkers P, Hommes T és mtsai Consequence of functional Nod2 and Tlr4 mutations
on gene transcription in Crohn’s disease patients. J Mol Med 2005;83: 601–609.
103 Lakatos PL, Lakatos L, Szalay F és mtsai Toll-like receptor 4 and NOD2/CARD15 mutations
in Hungarian patients with Crohn disease: phenotype-genotype correlations. World J
Gastroenterol 2005;11:1489-95.
104 * Oostenbrug LE, Drenth JP, de Jong DJ és mtsai Association between Toll-like receptor 4 and
infl ammatory bowel disease. Infl amm Bowel Dis 2005;11:567-75.
105 Fernandez L, Martinez A, Mendoza JL és mtsai Interleukin-10 polymorphisms in Spanish
patients with IBD. Infl amm Bowel Dis 2005;11:739-43.
106 KLAUSZ G, MOLNAR T, NAGY F és mtsai Polymorphism of the heat-shock protein gene Hsp70-
2, but not polymorphisms of the IL-10 and CD14 genes, is associated with the outcome of
Crohn’s disease. Scand J Gastroenterol 2005;40:1197-1204.
107 Martinez A, Del Carmen Martin M, Mendoza JL és mtsai Association of the organic cation
transporter OCTN genes with Crohn’s disease in the Spanish population. Eur J Hum Genet.
2005 Dec 7; [Epub ahead of print]
108 * Newman B, Gu X, Wintle RF és mtsai A risk haplotype in the solute carrier family 22A4/
22A5 gene cluster infl uences phenotypic expression of Crohn’s disease. Gastroenterology
2005;128:260-9.
109 NOBLE CL, NIMMO ER, DRUMMOND H és mtsai The Contribution of OCTN1/2 Variants Within
the IBD5 Locus to Disease Susceptibility and Severity in Crohn’s Disease. Gastroenterology
2005;129:1854-64.
110 * Török HP, Glas J, Tonenchi L és mtsai Polymorphisms in the DLG5 and OCTN cation
transporter genes in Crohn’s disease. Gut 2005;54:1421–1427.
111 Crawford NP, Eichenberger MR, Colliver DW és mtsai Evaluation of SLC11A1 as an infl ammatory
bowel disease candidate gene. BMC Med Genet 2005;6:10, published online before print.
112 TOSA M, NEGORO K, KINOUCH Y és mtsai Lack of association between IBD5 and Crohn’s
disease in Japanese patients demonstrates population-specifi c differences in infl ammatory
bowel disease. Scand J Gastroenterol 2005;41:48-53.
113 Daly MJ, Pearce AV, Farwell L és mtsai Association of DLG5 R30Q variant with infl ammatory
bowel disease. Eur J Hum Genet 2005;13:835-9.
114 Noble CL, Nimmo ER, Drummond H és mtsai DLG5 variants do not infl uence susceptibility to
infl ammatory bowel disease int he Scottish population. Gut 2005;54:1416-20.
115 * VERMEIRE S, PIERIK M, HLAVATY T és mtsai Association of Organic Cation Transporter
Risk Haplotype With Perianal Penetrating Crohn’s Disease but Not With Susceptibility to IBD.
Gastroenterology 2005;129:1845-53.
116 Urcelay E, Mendoza JL, Martin MC és mtsai MDR1 Gene: Susceptibility in Spanish Crohn’s
Disease and Ulcerative Colitis Patients. Infl amm Bowel Dis 2006;12:33-37.
117 HO GT, NIMMO ER, TENESA A és mtsai Allelic Variations of the Multidrug Resistance
Gene Determine Susceptibility and Disease Behavior in Ulcerative Colitis. Gastroenterology
2005;128:288-96.
118 Machida H, Tsukamoto K, Wen CY és mtsai Crohn’s disease in Japanese is associated with a
SNP-haplotype of N-acetyltransferase 2 gene. World J Gastroenterol 2005; 11: 4833-4837.
119 Machida H, Tsukamoto K, Wen CY, és mtsai Association of polymorphic alleles of CTLA4 with
infl ammatory bowel disease in the Japanese. World J Gastroenterol 2005; 11: 4188-4193.
120 Kader HA, Tchernev VT, Satyaraj E és mtsai Protein microarray analysis of disease activity in
pediatric infl ammatory bowel disease demonstrates elevated serum PLGF, IL-7, TGF-beta1,
and IL-12p40 levels in Crohn’s disease and ulcerative colitis patients in remission versus active
disease. Am J Gastroenterol 2005;100:414-23.
121 Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining
disease susceptibility and phenotype in infl ammatory bowel disease. Am J Gastroenterol
2005;100:1134-42.
122 Levine A, Karban A, Eliakim R és mtsai A polymorphism in the TNF-alpha promoter gene is
associated with pediatric onset and colonic location of Crohn’s disease. Am J Gastroenterol
2005;100:407-13.
123 Waschke KA, Villani AC, Vermeire S és mtsai A polymorphism in the TNF-alpha promoter gene
is associated with pediatric onset and colonic location of Crohn’s disease. Am J Gastroenterol
2005;100:407-13.
124 Yamazaki K, McGovern D, Ragoussis J és mtsai Single nucleotide polymorphisms in TNFSF15
confer susceptibility to Crohn’s disease. Hum Mol Genet 2005;14:3499-3506.
125 Spina L, Saibeni S, Battaglioli T és mtsai Thrombosis in infl ammatory bowel diseases: role of
inherited thrombophilia. Am J Gastroenterol 2005;100:2036-41.
126 Hlavaty T, Pierik M, Henckaerts L és mtsai Polymorphisms in apoptosis genes predict
response to infl iximab therapy in luminal and fi stulizing Crohn’s disease. Aliment Pharmacol
Ther 2005;22:613-26.
127 Urcelay E, Mendoza JL, Martinez A, és mtsai IBD5 polymorphisms in infl ammatory bowel
disease:association with response to infi ximab. World J Gastroenterol 2005;11:1187-92.
128Sipos F, Molnar B, Zagoni T és mtsai Growth in Epithelial Cell Proliferation and Apoptosis Correlates
Specifi cally to the Infl ammation Activity of Infl ammatory Bowel Diseases: Ulcerative Colitis Shows
Specifi c p53- and EGFR Expression Alterations. Dis Colon Rectum 2005;48:775-86.
129 Chen R, Bronner MP, Crispin DA és mtsai Characterization of genomic instability in ulcerative
colitis neoplasia leads to discovery of putative tumor suppressor regions. Cancer Genetics
and Cytogenetics 2005;162: 99-106.
130 Aust DE, Haase M, Dobryden L és mtsai Mutations of the BRAF gene in ulcerative colitisrelated
colorectal carcinoma. Int J Cancer 2005;115:673-7.
131 * SCHULMANN K, MORI Y, CROOG V és mtsai Molecular Phenotype of Infl ammatory Bowel
Disease–Associated Neoplasms With Microsatellite Instability. Gastroenterology;129:74-85.
132 * TAHARA T, INOUE N, HISAMATSU T és mtsai Clinical signifi cance of microsatellite instability
in the infl amed mucosa for the prediction of colonic neoplasms in patients with ulcerative
colitis. J Gastroenterol Hepatol 2005; 20: 710–715.
133van der Veek PP, van den Berg M, de Kroon YE és mtsai Role of tumor necrosis factor-alpha and
interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-6.
134 Mohammed I, Cherkas LF, Riley SA és mtsai Genetic infl uences in irritable bowel syndrome:
a twin study. Am J Gastroenterol 2005;100:1340-4.
135 SAITO YA, PETERSEN GM, LOCKE GR és mtsai The Genetics of Irritable Bowel Syndrome.
Clin gastroenterol Hepatol 2005;3:1057-65.
136 Fernandez-Banares F, Esteve M, Farre C és mtsai Predisposing HLA-DQ2 and HLA-DQ8
haplotypes of coeliac disease and associated enteropathy in microscopic colitis. Eur J
Gastroenterol Hepatol 2005;17:1333–1338.
Genetika, pathológia | 379
380 | Gastro Update 2006
137 * Nam SW, Park JY, Ramasamy A és mtsai Molecular Changes From Dysplastic Nodule to
Hepatocellular Carcinoma Through Gene Expression Profi ling. HEPATOLOGY 2005;42: 809-818.
138 Mao HJ, Li HN, Zhou XM, és mtsai Monitoring microarray-based gene expression profi le
changes in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 2811-2816.
139 * Kato N, Ji G, Wang Y és mtsai Large-Scale Search of Single Nucleotide Polymorphisms for
Hepatocellular Carcinoma Susceptibility Genes in Patients With Hepatitis C. HEPATOLOGY
2005;42:846-853.
140 Yamada Y, Jackson-Grusby L, Linhart H és mtsai Opposing effects of DNA hypomethylation
on intestinal and liver carcinogenesis. PNAS 2005;102:13580-5.
141 Yeo W, Wong N, Wong W-L és mtsai High frequency of promoter hypermethylation of RASSF1A
in tumor and plasma of patients with hepatocellular carcinoma. Liver International 2005: 25:
266–272.
142 Fautrel A, Andrieux L, Musso O és mtsai Overexpression of the two nucleotide excision repair
genes ERCC1 and XPC in human hepatocellular carcinoma. J Hepatol 2005;43:288-93.
143 Zhang SH, Cong WM, Xian ZH, és mtsa. Clinicopathological signifi cance of loss of heterozygosity
and microsatellite instability in hepatocellular carcinoma in China. World J Gastroenterol 2005;
11: 3034-3039.
144 Park JY, Park WS, Nam SW, és mtsai Mutations of b-catenin and AXIN I genes are a late event
in human hepatocellular carcinogenesis. Liver International 2005: 25: 70–76.
145 Tseng CS, Tang KS, Lo HW, és mtsai UDP-glucuronosyltransferase 1A7 genetic polymorphisms
are associated with hepatocellular carcinoma risk and onset age. Am J Gastroenterol
2005;100:1758-63.
146 Wang H, Dai J, Hou S és mtsai Treatment of hepatocellular carcinoma with adenoviral vector
mediated Flt3 ligand gene therapy. Cancer Gene Therapy 2005;12:769-777.
147 Wirth T, Kuhnel F, Fleischmann-Mundt B és mtsai Telomerase-Dependent Virotherapy
Overcomes Resistance of Hepatocellular Carcinomas against Chemotherapy and Tumor
Necrosis Factor–Related Apoptosis-Inducing Ligand by Elimination of Mcl-1. Cancer Res
2005; 65: 7393-402.
148 Djojosubroto MW, Chin AC, Go N és mtsai Telomerase Antagonists GRN163 and GRN163L
Inhibit Tumor Growth and Increase Chemosensitivity of Human Hepatoma. HEPATOLOGY
2005;42:1127-1136.
149 Zhang SZ, Pan FY, Xu JF és mtsai Knockdown of c-Met by adenovirus-delivered small
interfering RNA inhibits hepatocellular carcinoma growth in vitro and in vivo. Mol Cancer Ther
2005;4:1577-84.
150 Lu X, Qin W, Li J és mtsai The Growth and Metastasis of Human Hepatocellular Carcinoma
Xenografts Are Inhibited by Small Interfering RNA Targeting to the Subunit ATP6L of Proton
Pump. Cancer Res 2005;65: 6843-9.
151 Stefani AL, Barzon L, Castagliuolo I és mtsai Systemic effi cacy of combined suicide/cytokine
gene therapy in a murine model of hepatocellular carcinoma. J Hepatol 2005;42:728-35.
152 Sakai M, Nishikawa M, Thanaketpaisarn O és mtsai Hepatocyte-targeted gene transfer by
combination of vascularly delivered plasmid DNA and in vivo electroporation. Gene Therapy
2005;12: 607-616.
153 Fu GF, Li X, Hou YY és mtsai Bifi dobacterium longum as an oral delivery system of endostatin
for gene therapy on solid liver cancer. Cancer Gene Therapy 2005;12:133-140.
154 Ma H, Liu Y, Liu S és mtsai Oral Adeno-Associated Virus-sTRAIL Gene Therapy Suppresses
Human Hepatocellular Carcinoma Growth in Mice. HEPATOLOGY 2005;42:1355–1363.
155 Foja S, Goldberg M, Schagdarsurengin U, és mtsai Promoter methylation and loss of coding
exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas. Liver
International 2005: 25:1202–1208.
156 Khan SA, Thomas HC, Toledano MB, és mtsai p53 mutations in human cholangiocarcinoma:
a review. Liver International 2005: 25: 704–716.
157 * Hillebrandt S, Washmuth HE, WeiskirchenR és mtsai Complement faktor 5 is a quantitative
trait gene that modifi es liver fi brogenesis in mice and humans. Nat Genet 2005;37:835-43.
158 * ASSELAH T, BIÈCHE I, LAURENDEAU I és mtsai Liver Gene Expression Signature of Mild
Fibrosis in Patients With Chronic Hepatitis C. Gastroenterology 2005;129:2064-75.
159 Adinolfi LE, Ingrosso D, Cesaro G és mtsai Hyperhomocysteinemia and the MTHFR C677T
Polymorphism Promote Steatosis and Fibrosis in Chronic Hepatitis C. HEPATOLOGY
2005;41:995–1003.
160 * Goulding C, Murphy A, MacDonald G és mtsai The CCR5-D32 mutation: impact on disease
outcome in individuals with hepatitis C infection from a single source. Gut 2005;54:1157–
1161.
161 Hohler T, Reuss E, Freitag CM és mtsai A Functional Polymorphism in the IL-10 Promoter
Infl uences the Response After Vaccination With HBsAg and Hepatitis A. HEPATOLOGY
2005;42: 72-76.
162 * Chen L, Borozan I, Feld J és mtsai Hepatic gene expression discriminates responders
and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology
2005;128:1437-44.
163 Yeung E, Chung RT. Microarrays and Prediction of Interferon Response in Chronic Hepatitis
C: Not Yet Ready for Prime Time. Clin Gastroenterol Hepatol 2005;3:1192-4.
164 Korf M, Jarczak D, Beger C és mtsai Inhibition of hepatitis C virus translation and subgenomic
replication by siRNAs directed against highly conserved HCV sequence and cellular HCV
cofactors. J Hepatol 2005;43:225-34.
165 Jopling CL, Yi M, Lancaster AM és mtsai Modulation of Hepatitis C Virus RNA Abundance by
a Liver-Specifi c MicroRNA. Science 2005;309: 1577-81.
166 * Morrissey DV, Blanchard K, Shaw L és mtsai Activity of Stabilized Short Interfering RNA in a
Mouse Model of Hepatitis B Virus Replication. HEPATOLOGY 2005;41:1349-1356.
167 * Uprichard SL, Boyd B, Althage A és mtsai Clearance of hepatitis B virus from the liver of
transgenic mice by short hairpin RNAs. PNAS 2005;102:773-8.
168 Arbuthnot P, Carmona S, Ely A. Exploiting the RNA interference pathway to counter HBV
replication. Liver International 2005: 25: 9–15.
169 Taylor JA, Naoumov NV. The potential of RNA interference as a tool in the management of viral
hepatitis. J Hepatol 2005;42:139-44.
170 Tsui TY, Lau CK, Ma J és mtsai rAAV-Mediated Stable Expression of Heme Oxygenase-1 in
Stellate Cells: A New Approach to Attenuate Liver Fibrosis in Rats. HEPATOLOGY 2005;42:335-
342.
171 Hiraide A, Imazeki F, Yokosuka O, és mtsai Fas polymorphisms infl uence susceptibility to
autoimmune hepatitis. Am J Gastroenterol 2005;100:1322-9.
172 Honda M, Kawai H, Shirota Y és mtsai Differential gene expression profi les in stage I primary
biliary cirrhosis. Am J Gastroenterol 2005;100:2019-30.
173 Honda M, Kawai H, Shirota Y és mtsai cDNA microarray analysis of autoimmune hepatitis, primary
biliary cirrhosis and consecutive disease manifestation. J Autoimmun 2005;25:133-40.
174 FAN L, TU X, ZHU Y és mtsai Genetic association of vitamin D receptor polymorphisms with
autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J Gastroenterol Hepatol
2005;20:249-55.
175 Fan LY, Tu XQ, Zhu Y, és mtsai Genetic association of cytokines polymorphisms with autoimmune
hepatitis and primary biliary cirrhosis in the Chinese. World J Gastroenterol 2005; 11: 2768-
2772.
176 Hagymasi K, Tulassay Z. Genetics of primary biliary cirrhosis. Orv Hetil 2005;146:2151-55.
177 * Younossi ZM, Baranova A, Ziegler K és mtsai A Genomic and Proteomic Study of the Spectrum
of Nonalcoholic Fatty Liver Disease. HEPATOLOGY 2005;42:665-674.
178 Younossi ZM, Gorreta F, Ong JP, és mtsai Hepatic gene expression in patients with obesityrelated
non-alcoholic steatohepatitis. Liver International 2005: 25: 760–771.
Genetika, pathológia | 381
382 | Gastro Update 2006
179 Baranova A, Schlauch K, Gowder S, ás mtsai Microarray technology in the study of obesity
and non-alcoholic fatty liver disease. Liver International 2005: 25: 1091–1096.
180 Oliver J, Agundez JAG, Morales S, és mtsai Polymorphisms in the transforming growth factorb1
gene (TGF-b1) and the risk of advanced alcoholic liver disease. Liver International 2005:
25: 935–939.
181 Martins A, Cortez-Pinto H, Machado M, és mtsai Are genetic polymorphisms of tumour necrosis
factor alpha, interleukin-10, CD14 endotoxin receptor or manganese superoxide dismutase
associated with alcoholic liver disease? Eur J Gastroenterol Hepatol 2005;17:1099-1104.
182 LADERO JM, MARTINEZ C, GARCIA-MARTIN E és mtsai Polymorphisms of the glutathione
S-transferases mu-1 (GSTM1) and theta-1 (GSTT1) and the risk of advanced alcoholic liver
disease. Scand J Gastroenterol 2005;40:348-53.
183 Meiler C, Mühlbauer M, Johann M, és mtsai Different effects of a CD14 gene polymorphism
on disease outcome in patients with alcoholic liver disease and chronic hepatitis C infection.
World J Gastroenterol 2005; 11: 6031-6037.
184 Mullenbach R, Bennett A, Tetlow N és mtsai ATP8B1 mutations in British cases with intrahepatic
cholestasis of pregnancy. Gut 2005;54:829–834.
185 HARRIS MJ, LE COUTEUR DG, ARIAS IM. Progressive familial intrahepatic cholestasis: Genetic
disorders of biliary transporters. J Gastroenterol Hepatol 2005;20: 807–817.
186 Ka C, Le Gac G, Dupradeau FY és mtsai The Q283P amino-acid change in HFE leads to
structural and functional consequences similar to those described for the mutated 282Y HFE
protein. Hum Genet 2005;117:467-75.
187 * Mimeault M, Brand R, Sasson A és mtsai Recent Advances on the Molecular Mechanisms
Involved in Pancreatic Cancer Progression and Therapies. Pancreas 2005;31:301-316.
188 Toyoda E, Doi R, Koizumi M és mtsai Analysis of E-, N-Cadherin, alpha-, beta-, and gammaCatenin
Expression in Human Pancreatic Carcinoma Cell Lines. Pancreas 2005;30:168-173.
189 Li D, Ahmed M, Li Y és mtsai 5,10-Methylenetetrahydrofolate Reductase Polymorphisms and
the Risk of Pancreatic Cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1470–6.
190 WANG L, MIAO X, TAN W és mtsai Genetic Polymorphisms in Methylenetetrahydrofolate
Reductase and Thymidylate Synthase and Risk of Pancreatic Cancer. Clin Gastroenterol
Hepatol 2005;3:743-51.
191 Nowak NJ, Gaile D, Conroy JM és mtsai Genome-wide aberrations in pancreatic
adenocarcinoma. Cancer Genetics and Cytogenetics 2005;161: 36-50.
192 * Prasad NB, Biankin AV, Fukushima N és mtsai Gene Expression Profi les in Pancreatic
Intraepithelial Neoplasia Refl ect the Effects of Hedgehog Signaling on Pancreatic Ductal
Epithelial Cells. Cancer Res 2005;65:1619-26.
193 Yeh TS, Ho YP, Chiu CT és mtsai Aberrant Expression of cdx2 Homeobox Gene in Intraductal
Papillary- Mucinous Neoplasm of the Pancreas But Not in Pancreatic Ductal Adenocarcinoma.
Pancreas 2005;30:233-238.
194 * YAN L, MCFAUL C, HOWES N és mtsai Molecular Analysis to Detect Pancreatic Ductal
Adenocarcinoma in High-Risk Groups. Gastroenterology 2005;128:2124-30.
195 Kasuya H, Takeda S, Nomoto S és mtsai The potential of oncolytic virus therapy for pancreatic
cancer. Cancer Gene Therapy 2005;12: 725-736.
196 Hata T, Furukawa T, Sunamura M és mtsai RNA Interference Targeting Aurora Kinase A
Suppresses Tumor Growth and Enhances the Taxane Chemosensitivity in Human Pancreatic
Cancer Cells. Cancer Res 2005;65: 2899-905.
197 Pratesi G, Petrangolini G, Tortoreto M és mtsai Therapeutic Synergism of Gemcitabine and
CpG Oligodeoxynucleotides in an Orthotopic Human Pancreatic Carcinoma Xenograft. Cancer
Res 2005; 65: 6388-93.
198 Duxbury MS, Ito H, Benoit E és mtsai RNA Interference Demonstrates a Novel Role for
Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine
Chemoresistance. Clin Cancer Res 2005;11:3433-8.
199 Ocker M, Neureiter D, Lueders M és mtsai Variants of bcl-2 specifi c siRNA for silencing
antiapoptotic bcl-2 in pancreatic cancer. Gut 2005;54:1298–1308.
200 Tukiainen E, Kylanpaa ML, Kemppainen E és mtsai Pancreatic Secretory Trypsin Inhibitor
(SPINK1) Gene Mutations in Patients With Acute Pancreatitis. Pancreas 2005;30:239-242.
201 LEMPINEN M, PAJU A, KEMPPAINEN E és mtsai Mutations N34S and P55S of the SPINK1
gene in patients with chronic pancreatitis or pancreatic cancer and in healthy subjects: A
report from Finland. Scand J Gastroenterol 2005;40:225-30.
202 Bendicho MT, Guedes JC, Silva NN és mtsai Polymorphism of Cytokine Genes (TGF-[beta]1,
IFN-[gamma], IL-6, IL-10, and TNF-[alpha]) in Patients With Chronic Pancreatitis. Pancreas
2005;30:333-336.
203 Balog A, Gyulai Z, Boros LG és mtsai Polymorphism of the TNF-a, HSP70-2, and CD14 Genes
Increases susceptibility to Severe Acute Pancreatitis. Pancreas 2005;30:C46-C50.
204 Zhang DL, Zheng HM, Yu BJ, Association of polymorphisms of IL and CD14 genes with acute
severe pancreatitis and septic shock. World J Gastroenterol 2005;11: 4409-4413.
205 Bradley SP, Rastellini C, da Costa MA és mtsai Gene Silencing in the Endocrine Pancreas
Mediated by Short-Interfering RNA. Pancreas 2005;31:373-379.
